Eon Labs of the USA has received final approval from the US Food and Drug Administration for the antibacterial agent nitrofurantoin monohydrate, 100mg capsules, the generic equivalent of Procter & Gamble's Macrobid, and the company will begin shipping the product immediately.
The firm is a generic pharmaceutical company specializing in the development, licensing, manufacture and distribution of a broad range of prescription pharmaceutical products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze